Beta
Atropine
medication Under reviewAtropine is a naturally occurring alkaloid extracted from plants such as belladonna and used as a muscarinic antagonist that blocks acetylcholine at muscarinic receptors in the parasympathetic nervous system. This inhibition reduces parasympathetic activity, leading to effects like increased heart rate, pupil dilation, and reduced glandular secretions. It is administered in various forms, including ophthalmic drops for eye-related applications and systemic routes for cardiovascular modulation. In healthy individuals, atropine primarily influences autonomic functions, enhancing sympathetic responses by counteracting vagal tone. For instance, it amplifies heart rate increases during exercise or beta-adrenergic stimulation and slows myopia progression in children through low-dose eye drops by mechanisms that may involve scleral remodeling or reduced ocular growth signals. General health applications are limited due to its potent pharmacological effects, focusing on acute interventions rather than routine supplementation.
Research summary
Scientific evidence on atropine in healthy humans centers on its cardiovascular and ocular effects, with randomized trials showing low-dose ophthalmic atropine slows myopia progression in children, particularly at 0.01% concentration over three years. Studies in adults demonstrate it enhances heart rate responses to exercise and beta-agonists by blocking vagal inhibition, with milder effects on cardiac contractility. Overall consensus supports its efficacy in specific autonomic modulations, though systemic use is constrained by side effects, and it is not positioned as a general supplement.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Atropine to your stack to report effects
Impact of coronavirus disease 2019 restrictions on the efficacy of atropine 0.01% eyedrops for myopia control - Findings from the Western Australia Atropine for the Treatment of Myopia study.
Not specified
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.
Zadnik K, Schulman E, Flitcroft I, et al.
No reports yet
Be the first to report this effect and help the community.
Add Atropine to your stack to report effects
Impact of coronavirus disease 2019 restrictions on the efficacy of atropine 0.01% eyedrops for myopia control - Findings from the Western Australia Atropine for the Treatment of Myopia study.
Not specified
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.
Zadnik K, Schulman E, Flitcroft I, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Atropine to your stack to report effects
Impact of coronavirus disease 2019 restrictions on the efficacy of atropine 0.01% eyedrops for myopia control - Findings from the Western Australia Atropine for the Treatment of Myopia study.
Not specified
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.
Zadnik K, Schulman E, Flitcroft I, et al.
No reports yet
Be the first to report this effect and help the community.
Add Atropine to your stack to report effects
Impact of coronavirus disease 2019 restrictions on the efficacy of atropine 0.01% eyedrops for myopia control - Findings from the Western Australia Atropine for the Treatment of Myopia study.
Not specified
Research (2 studies)
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.
Zadnik K, Schulman E, Flitcroft I, et al.
Impact of coronavirus disease 2019 restrictions on the efficacy of atropine 0.01% eyedrops for myopia control - Findings from the Western Australia Atropine for the Treatment of Myopia study.
Not specified
Community updates
No updates yet for this supplement.
Be the first to share your experience!